<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03807453</url>
  </required_header>
  <id_info>
    <org_study_id>IstanbulMU2</org_study_id>
    <nct_id>NCT03807453</nct_id>
  </id_info>
  <brief_title>Comparison of Scalp Microbiome of the Psoriasis and Seborrheic Dermatitis Patients</brief_title>
  <official_title>Comparison of Scalp Microbiome of the Patients With Psoriasis Vulgaris and Seborrheic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Medeniyet University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Turkish Dermatology Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istanbul Medeniyet University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A sterile swap specimen taken from the scalp of the patients with psoriasis vulgaris or
      seborrheic dermatitis and the volunteer control group will be examined in our study. The
      examples of the microbiome of the patients will be taken both the lesional scalp and the
      lesion-free part of the scalp. Then, the microbiome differences between the lesioned scalp
      and the lesion-free scalp of both groups, and the microbiome differences between the two
      groups and the control group will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2019</start_date>
  <completion_date type="Actual">June 18, 2019</completion_date>
  <primary_completion_date type="Actual">June 18, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The scalp microbiome of the patients with psoriasis and seborrheic dermatitis</measure>
    <time_frame>6 months</time_frame>
    <description>The aim of this study is to compare the scalp microbiome of psoriasis vulgaris and seborrheic dermatitis both the lesion and lesion-free parts and also the control group and to assess their role on etiopathogenesis. Determining the microbiota of this region which is frequently involved and resistant to treatment may change the treatment approach. In addition, scalp microbiome of seborrheic dermatitis may be a causal factor of rapid relapse after treatment.
The similarities between the microbiota of the psoriasis vulgaris and seborrheic dermatitis cases with only scalp involvement can guide us not only for the diagnosis but also the treatment. There are a few reports about the role of Malassezia subgroups in the pathogenesis, but it is known that there are many different flora members on the scalp. Exposing these can change both our diagnosis and treatment options.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The differences between the scalp microbiome of different countries</measure>
    <time_frame>6 months</time_frame>
    <description>Does the microbiota of the patients change between the countries? To our knowledge, there is no similar studies in present. Presenting the scalp microbiome of Turkish population can be a start to understand whether there is a difference in terms of the countries.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <condition>Seborrheic Dermatitis</condition>
  <condition>Microbial Colonization</condition>
  <arm_group>
    <arm_group_label>Psoriasis Vulgaris patients-Lesion</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis Vulgaris patients-Lesion free</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Seborrheic Dermatitis-Lesion</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Seborrheic Dermatitis-Lesion free</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Microbiome</intervention_name>
    <description>The scalp microbiome</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Psoriasis Vulgaris patients-Lesion</arm_group_label>
    <arm_group_label>Psoriasis Vulgaris patients-Lesion free</arm_group_label>
    <arm_group_label>Seborrheic Dermatitis-Lesion</arm_group_label>
    <arm_group_label>Seborrheic Dermatitis-Lesion free</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic and community sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with scalp psoriasis

          2. Patients with seborrheic dermatitis

          3. Agree to participate in research 4 - Do not use any drugs for their disease topically
             or systemically for two months

        Exclusion Criteria:

          1. Patients who do not want to participate in the study

          2. Patients with psoriasis vulgaris or seborrheic dermatitis that does not effect scalp.

          3. Those with chronic diseases that may affect skin microbiome

          4. Patients using antibiotics, antifungal or antiviral therapy for any reason for the
             last one month.

          5. Patients who are using topical or systemic drugs for their illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Melek Aslan Kayıran</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 5, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2019</study_first_posted>
  <last_update_submitted>June 30, 2019</last_update_submitted>
  <last_update_submitted_qc>June 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Medeniyet University</investigator_affiliation>
    <investigator_full_name>Melek Aslan Kayıran</investigator_full_name>
    <investigator_title>Dermatologist, M.D.</investigator_title>
  </responsible_party>
  <keyword>Psoriasis Vulgaris</keyword>
  <keyword>Seborrheic Dermatitis</keyword>
  <keyword>Scalp</keyword>
  <keyword>Microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Seborrheic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

